

FINANCIAL RESULTS for Q1 FY2026

Fiscal Year Ending March 2027

JEOL Ltd.

Aug 14, 2026

INDEX

1. Q1 FY2026 Financial Results

Summary of Q1 FY2026 Results

Q1 FY2026 Results		Despite year-on-year declines in net sales and operating profit, results were largely in line with plan. Net Sales: ¥24.5 billion (YoY -39.1%) Operating Profit: -¥2.0 billion (YoY –)
Scientific and Metrology Instruments	Universities / Government	■ Japan: Demand remained solid, supported by continued R&D investment in science and technologies. ■ U.S.: Market conditions remained uncertain due to changes in research funding and government policies. ■ Europe: Demand remained weak amid sluggish economic conditions and geopolitical uncertainties. ■ China / Asia: Despite the continued impact of U.S.-China relations and trade policies, demand remained solid, supported by R&D and industrial investment, particularly in India. In China, net sales declined year on year, partly due to delays in the renewal process for the import duty exemption program applicable to universities and research institutions. However, order intake remained relatively solid, indicating resilient underlying demand.
	Semiconductor	■ As investment in AI-related technologies and advanced semiconductors continues to grow, customer evaluations of TEM and FIB systems for inspection applications are progressing steadily. Various initiatives are underway to accelerate adoption and secure new projects.
	Life Science	■ Enhancing sales efforts and product development.
Industrial Equipment	Lithography System	■ Multi-Beam Mask Writer: Customer inquiries continue to increase, while demand is recovering gradually. ■ Single-Beam Mask Writer: Demand temporarily softened due to tighter export controls and moderating demand in China. ■ Spot Beam (Spot type Electron Beam Lithography System): Demand remains robust, supported mainly by production applications for optical devices used in AI data centers.
FY2026 Forecast		Previous forecasts for both the first half and full year remain unchanged.

Q1 FY2026 Results (P/L)

- Consolidated net sales ¥24.5 billion (-39.1% YoY), Operating Profit: -¥2.0 billion yen (－YoY)
- Although net sales and profit declined year on year due to the timing of revenue recognition for certain projects and tighter export controls, results were broadly in line with the initial plan, and business performance remained on track.

Consolidated figures (P/L) (100 million JPY)

		FY2025 Q1 YTD (1)	FY2026 Q1 YTD (2)	YoY (2) - (1)
1	Net sales	401	245	- 157
2	Sales cost	207	127	- 80
3	(Cost rate)	51.5%	51.9%	0.4%
4	Gross profit	195	118	- 77
5	SGA	105	111	6
6	R&D cost	31	26	- 5
7	SGA total	137	137	1
8	Operating profit	58	- 20	- 78
9	Non-operating income	6	7	2
10	Non-operating expenses	6	1	- 4
11	Ordinary profit	58	- 14	- 71
12	Extraordinary income	10	2	- 8
13	Extraordinary loss	0	0	0
14	Net profit before tax	68	- 12	- 80
15	Corporate taxes	21	5	- 16
16	Net profit	47	- 17	- 64
	Exchange rate (1$=)	¥145	¥161	
	Exchange rate (1€=)	¥164	¥185	

Factors for fluctuating ordinary profit (YoY)

(JPY in millions)

(A) Positive Factors	15
1. FX impact (yen depreciation)	10
2. R&D cost decrease	5
(B) Negative Factors	- 93
1. Sales volume decrease, etc.	- 87
2. SGA increase	- 6
(A)+(B)	- 78

Factors of Increase/Decrease in Profit



Transition of Consolidated Sales & Operating Profit by Segment (Q1 FY2026)

- Scientific/Metrology Instruments: Demand led by electron microscopes remained solid. However, the outlook remained uncertain due to geopolitical risks and policy developments.
- Industrial Equipment: Net sales decreased year on year, reflecting the timing of revenue recognition for certain Multi-Beam Mask Writer projects and the impact of tighter export controls on Single-Beam Mask Writers. Meanwhile, orders for Spot-Beam Electron Beam Lithography Systems remained solid.

(100 million JPY)

		FY2025 Q1 YTD	FY2026 Q1 YTD	YoY Changes	YoY %
Company Total	Net sales	401	245	-157	-39.1%
	Operating profit	58	-20	-78	—
	OP margin	14.4%	-8.0%	-22.4%	—
	Ordinary profit	58	-14	-71	—
	Net profit	47	-17	-64	—
Scientific/Metrology Instruments	Net sales	214	195	-19	-8.8%
	Operating profit	-4	-3	1	—
	OP margin	-1.8%	-1.4%	0.4%	—
Industrial Equipment	Net sales	145	50	-95	-65.6%
	Operating profit	72	2	-70	-96.9%
	OP margin	49.7%	4.4%	-45.3%	—
Medical Equipment	Net sales	43	—	-43	—
	Operating profit	7	—	-7	—
	OP margin	16.0%	—	—	—
Company Total	Expenses	17	19	2	11.9%
	Exchange rate (1$=)	¥145	¥161	¥15	10.6%
	Exchange rate (1 € =)	¥164	¥185	¥21	12.8%

Change in Major Accounts

(100 million JPY)

(Consolidated)	FY24 Result	FY25 result	FY26 Forecast
1 Inventory	770	755	647
2 Interest-bearing debt (including lease liabilities, etc.)	93	271	198
3 Total assets	2,225	2,240	2,461
4 Net Assets (capital-to-asset)	1,367 (61.4%)	1,449 (59.9%)	1,590 (64.6%)
5 Dividend(JPY)	106	132	132
6 Capital investment	70	202	230
7 Depreciation cost	49	54	65
8 Consolidated orders received	1,864	1,801	1,700*
9 Consolidated order backlog	1,032	1,039	1,050*
10 Overseas sales ratio	71.2%	67.2%	68.0%

* Medical Equipment Business excluded from order intake from FY2026 due to the business transfer.

Investment efficiency index

1 ROE	14.3%	15.7%	14.0%
2 ROIC*	18.1%	12.3%	11.2%
3 PBR	1.7	1.9	ー

* In accordance with our internal management standard

Transition of Consolidated Orders, Sales and Backlog



Solutions for Innovation JEOL

2. Business Topics

New Products and Solutions

- Introduced new products and solutions for the semiconductor and life science markets
- Strengthened next-generation analytical platforms leveraging AI and automation technologies

A: Evolution of Product Value

Enhance product competitiveness through technological and functional advancements, creating new value beyond a conventional successor model.

ACE eye™
Semiconductor TEM

Addressing demand for advanced semiconductor process monitoring and inspection equipment

GRAND ARM™ 3
Atomic Resolution Analytical Microscope

Enabling atomic-scale in-situ observation and dynamic analysis to accelerate the development of next-generation materials.

NeoScope™ | JCM-7000PLUS
Benchtop SEM

Contributing to operational efficiency in R&D and quality control applications

B: Strengthening Competitiveness

Improve performance and functionality in line with market needs, reinforcing competitive advantage and supporting market share expansion.

CRYO ARM™300S／CRYO ARM™200S
Cryo TEM



Addressing demand from the drug discovery and structural biology research

C: Creation of New Markets

Leverage proprietary technologies to introduce innovative products, creating new market opportunities and expanding growth areas.

LazEdge
Laser SEM system

Addressing a broad range of analytical needs for high-speed, high-precision processing of large-area samples across the semiconductor, battery, and metals sectors

2. Targets and Focus Areas in the Medium-term Management Plan ″Evolving Growth 2.0 -A New Horizon-”

Medium-term Management Plan Target 【Financial】

- Further strengthen capital efficiency-oriented management and "earning power" of core businesses towards sustainable growth.
- To improve capital efficiency, set ROE/ROIC targets and follow up with PDCA cycle

		FY24 Result	FY25 Result	FY26 Forecast	FY29 Target	Growth Rate (FY24-29)	Measures
Improve profitability	Net Sales	196.7billion yen	179.4billion yen	164.0billion yen	205.0billion yen	CAGR 0.8%	• Create innovation • Strengthen focus area
	Operating profit	35.5billion yen	26.0billion yen	26.5billion yen	44.0billion yen	CAGR 4.4%	
	Operating margin	18.0%	14.5%	16.2%	21.5%	+3.5%pt	
	Exchange rate(1$=)	¥152	¥151	¥155	¥145		
	Exchange rate(1€=)	¥164	¥175	¥175	¥157		
Create returns more than investment costs	ROE	14.3%	15.7%	14.0%	15% or more	—	• Improve profitability and streamline operations • Strengthen shareholder returns
	ROIC*	18.1%	12.3%	11.2%	15% or more	—	

*Based on internal management standards

Medium-Term Management Plan Targets [Financial] | By Segment

- Enhance the profitability of Scientific/Metrology Instruments by positioning semiconductors and life sciences as priority areas and leveraging proprietary technologies. Improve operating profit margin by +7.1pt (12.0% → 19.1%).

Improvement in Operating Profit Margin (+7.1pt)		Main Measures	KPI
Increase in sales to priority areas	+4.1pt	• Improve product mix through increased sales of strategic products (FIB/TEM for semiconductor applications, etc.) • Improve gross profit margin through stricter pricing discipline and value-based pricing strategies	Sales to priority areas (semiconductors, etc.), gross profit margin
Improvement in service profitability	+1.5pt	• Increase maintenance contract ratio • Expand high-value-added services and strengthen pricing management • Improve service operation efficiency	Maintenance contract ratio, gross profit margin
Improvement in productivity profitability	+1.5pt	• Improve production efficiency via factory reorganization, smart factory initiatives, and shorter lead times.	Cost ratio, lead time

- Signs of recovery are emerging in the market environment for Multi-Beam Mask Writers, while strengthening responsiveness to strong demand for spot-beam systems.

		FY24 Result	FY25 Result	FY26 Forecast	FY29 Target	CAGR (FY24-29)
Scientific And Metrology Instruments	Net sales	¥124.8 billion yen	¥116.3 billion yen	¥121.4 billion yen	¥144.0 billion yen	2.9%
	Operating profit	¥15.0 billion yen	¥13.1 billion yen	¥16.4 billion yen	¥27.5 billion yen	12.9%
	Operating profit margin	12.0%	11.2%	13.5%	19.1%	+7.1pt
Industrial Equipment	Net sales	¥56.5 billion yen	¥48.1 billion yen	¥42.6 billion yen	¥61.0 billion yen	1.5%
	Operating profit	¥26.3 billion yen	¥19.4 billion yen	¥16.7 billion yen	¥23.0 billion yen	-2.6%
	Operating profit margin	46.6%	40.2%	39.3%	37.7%	-8.9pt
Medical Equipment	Net sales	¥15.4 billion yen	¥14.9 billion yen	—	—	—
	Operating profit	¥0.7 billion yen	¥0.1 billion yen	—	—	—
	Operating profit margin	4.3%	0.4%	—	—	—
Corporate expenses		¥6.5 billion yen	¥6.5 billion yen	¥6.7 billion yen	¥6.5 billion yen	
	Exchange rate(1$=)	¥152	¥151	¥155	¥145	
	Exchange rate(1€=)	¥164	¥175	¥175	¥157	

Priority Areas in this Medium-term Management Plan

- We will focus on semiconductors and life sciences—markets with strong growth potential—where our advanced technological capabilities are in high demand.

	Semiconductor	*Life Science*
		
Market Growth	Significant growth is expected in the market for advanced measurement and inspection instruments, driven by semiconductor miniaturization, densification, and rising demand.	With the growth of the life sciences market, demand for analytical instruments used in this field is also expected to increase.
Our Strengths	Provide high-precision instruments and services for semiconductor structure and failure analysis. Focus on automation to simplify analysis and reduce customer workload.	Provide highly precise instruments and services for atomic-level molecular structure analysis in the fields of structural biology and drug discovery.

Balance Sheet Management Policy

■ Promote enhancement of corporate value under the Medium-Term Management Plan through management conscious of capital costs and share price

Optimal capital structure with awareness of capital costs	■ Promote management conscious of capital costs and share price to achieve sustainable growth in corporate value ■ Maintain an appropriate equity ratio and D/E ratio while generating returns exceeding capital costs ■ Examine the appropriate level of cash and deposits required under various business conditions
Emphasis on investment discipline	■ Execute focused investments in semiconductor and life science priority areas while promoting growth investments with emphasis on investment efficiency ■ Strategic investments (M&A, etc.) will be evaluated with discipline, and additional shareholder returns will be considered if strategic investment opportunities are limited
Strengthen shareholder returns	■ Stable and continuous shareholder returns with a target payout ratio of approximately 30% are the basic policy ■ Flexible share repurchases will be considered to improve capital efficiency and achieve sustainable growth in corporate value (Repurchased ¥11.8 billion / 2.3 million shares in FY2025) ■ Treasury shares acquired may be utilized for M&A and stock compensation plans for officers and employees; however, recognizing that excessive holdings may reduce capital efficiency, cancellation of shares exceeding a certain level will be considered

Investment/Shareholder Returns

■ In light of the revision to the Medium-Term Management Plan resulting from the transfer of the Medical Equipment Business, establish a cash allocation policy aimed at further enhancing corporate value
Strengthen shareholder returns together with growth investments in priority areas, while evaluating strategic investments including M&A with discipline

Previous Plan (FY25-FY29)

Revised Plan Evolving Growth 2.0 -A New Horizon- (FY25-FY29)



＊Reflecting the impact of the transfer of the Medical Equipment Business

Initiatives for stable and continuous return to shareholders

- Aim to realize stable and continuous shareholder returns based on a basic policy of a target dividend payout ratio of 30%.
- The Company will consider flexible share repurchases aimed at enhancing capital efficiency and achieving sustainable growth in corporate value. (Repurchased 2.3 million shares for approximately 11.8 billion yen in FY2025)

Dividend Payout Ratio and Dividend Amount



Note on document handling

Information contained in this document is based on assumptions and beliefs derived from currently available data. Actual results may differ materially due to various known and unknown factors, including economic trends, semiconductor industry cycles, and changes in R&D spending.